Day | Untreated control | Lotilaner | Comparison | ||||
---|---|---|---|---|---|---|---|
Mean | Range | Mean | Range | Geometric (arithmetic) mean efficacy (%) | |||
Study 2 | 2 | 25.5 (27.6) | 7–36 | 0.0 (0.0) | 0–0 | 100 (100) | t (13) = 19.1, P < 0.0001 |
9 | 25.1 (26.0) | 15–40 | 0.0 (0.0) | 0–0 | 100 (100) | t (14) = 32.0, P < 0.0001 | |
16 | 22.9 (24.5) | 9–36 | 0.1 (0.3) | 0–2 | 99.4 (99.0) | t (14) = 15.1, P < 0.0001 | |
23 | 28.6 (29.9) | 19–47 | 0.1 (0.1) | 0–1 | 99.7 (99.6) | t (14) = 23.9, P < 0.0001 | |
30 | 21.9 (23.4) | 10–35 | 0.1 (0.1) | 0–1 | 99.6 (99.5) | t (14) = 18.7, P < 0.0001 | |
37 | 26.1 (28.1) | 13–45 | 0.0 (0.0) | 0–0 | 100 (100) | t (13) = 23.3, P < 0.0001 | |
Study 3 | 2 | 5.2 (6.5) | 2–20 | 0.0 (0.0) | 0–0 | na | na |
9 | 14.3 (16.0) | 4–27 | 0.1 (0.1) | 0–1 | 99.4 (99.2) | t (7) = 12.7, P < 0.0001 | |
16 | 29.5 (31.0) | 14–43 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 27.8, P < 0.0001 | |
23 | 26.5 (27.8) | 17–42 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 29.2, P < 0.0001 | |
30 | 19.6 (20.4) | 12–31 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 28.4, P < 0.0001 | |
37 | 14.8 (15.3) | 10–25 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 31.5, P < 0.0001 | |
Study 4 | 2 | 34.2 (35.4) | 17–45 | 0.0 (0.0) | 0–0 | 100 (100) | t (4) = 37, P < 0.0001 |
9 | 33.6 (34.4) | 24–43 | 0.0 (0.0) | 0–0 | 100 (100) | t (4) = 49.6, P < 0.0001 | |
16 | 30.7 (31.4) | 19–42 | 0.0 (0.0) | 0–0 | 100 (100) | t (4) = 42.8, P < 0.0001 | |
23 | 29.9 (30.5) | 20–37 | 0.0 (0.0) | 0–0 | 100 (100) | t (4) = 51.9, P < 0.0001 | |
30 | 28.4 (29.5) | 16–39 | 0.0 (0.0) | 0–0 | 100 (100) | t (4) = 36.2, P < 0.0001 | |
37 | 27.2 (28.3) | 15–37 | 0.1 (0.1) | 0–1 | 99.7 (99.6) | t (4) = 33.5, P < 0.0001 |